Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7291016 | 1.00 | GRM2 (0.65) | GRM2SIGMAR1 | |
| SCHEMBL1223893 | 1.00 | GRM2 (0.65) | GRM2SIGMAR1 | |
| SCHEMBL1222976 | 0.88 | GRM2 (0.57) | GRM2SIGMAR1 | |
| SCHEMBL7299686 | 0.88 | GRM2 (0.64) | GRM2SIGMAR1 | |
| SCHEMBL1222977 | 0.88 | GRM2 (0.57) | GRM2SIGMAR1 | |
| SCHEMBL9844135 | 0.88 | GRM2 (0.64) | GRM2SIGMAR1 | |
| SCHEMBL12728925 | 0.87 | GRM2 (0.60) | GRM2SIGMAR1 | |
| SCHEMBL6960959 | 0.86 | GRM2 (0.57) | GRM2SIGMAR1 | |
| SCHEMBL8695799 | 0.86 | GRM2 (0.59) | GRM2SIGMAR1 | |
| SCHEMBL6966303 | 0.86 | GRM2 (0.59) | GRM2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039823-A1 | OXAZOLIDINONE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-02-17 | — | — | US | disclosed |
| EP-0964863-B1 | OXAZOLIDINES AS 5-HT2A-ANTAGONISTS | MERCK PATENT GMBH (DE) | 2003-05-21 | — | — | EP | disclosed |
| US-6462056-B1 | SUCH AS 3-(4-CHLOROPHENYL)-5-(4-(3-INDOLYL)-1-PIPERIDINYL-METHYL)OXAZOLIDIN-2-ONE; 5-HT2A ANTAGONISTS WITH 5-HT REUPTAKE INHIBITING, ANTIDEPRESSANT OR ANXIOLYTIC EFFECT | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2002-10-08 | — | — | US | disclosed |
| EP-0964863-A1 | OXAZOLIDINES AS 5-HT2A-ANTAGONISTS | MERCK PATENT GmbH (DE) | 1999-12-22 | — | — | EP | disclosed |
| WO-1998038189-A1 | OXAZOLIDINES AS 5-HT2A-ANTAGONISTS | MERCK PATENT GMBH (DE) | 1998-09-03 | — | — | WO | disclosed |
| EP-0635505-B1 | 4-Aryloxy- and 4-arylthiopiperidine derivatives | MERCK PATENT GMBH (DE) | 1997-10-15 | — | — | EP | disclosed |
| EP-0635505-A1 | 4-Aryloxy- and 4-arylthiopiperidine derivatives | MERCK PATENT GmbH (DE) | 1995-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039823-A1 | OXAZOLIDINONE ANTIBIOTICS | OXA1L, XDH, UBE2D3 | GRM2 2153/4885SIGMAR1 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.